Y-mabs closes deals in China and Europe for the firm's two drugs against pediatric cancer

According to these new deals, Y-mabs will pass on responsibility for the distribution of its drugs danyelza and omburtamab in China and Europe – the task will instead be passed onto various partners.

Photo: Kelly Davidson Photography

The Danish but US-listed biotech firm Y-mabs has entered two new partnerships in China and Eastern Europe, respectively.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Latest news

See all jobs